Spironolactone for hormonal acne: the evidence

Spironolactone is a decades-old blood pressure pill that dermatologists now reach for off-label to treat stubborn acne in adult women. The drug blocks androgens, the hormones that drive oily skin and clogged pores, and a wave of recent trials has finally given it the kind of evidence it lacked for years. This guide walks through how it works, what the best studies actually show, where the evidence is still thin, and who should and shouldn't consider it.

One thing up front. Nothing here is medical advice. Spironolactone is a prescription drug with real risks, and the right call depends on your health history. Talk to a clinician before starting or stopping anything.

What spironolactone is and why it ended up treating acne

Spironolactone hit the U.S. market in 1960 as a diuretic and blood pressure drug. Its main job is to block aldosterone, a hormone that controls salt and water balance. The FDA still approves it for heart failure, resistant high blood pressure, fluid buildup from liver or kidney disease, and a few related conditions. Acne is nowhere on that list.

So why do dermatologists prescribe it for skin? Because spironolactone has a useful side effect: it's a weak anti-androgen. Androgens like testosterone and dihydrotestosterone (DHT) tell your oil glands to pump out more sebum and tell skin cells to grow faster. Too much of both clogs pores and feeds acne bacteria. Block the androgens, and you turn down the oil.

This is why spironolactone works best for a specific kind of breakout. Think jawline and lower-face acne in adult women, the kind that flares before a period and shrugs off the usual creams. That pattern points to hormones, and that's exactly where this drug earns its keep.

How it works in the skin

Spironolactone fights acne through a few overlapping actions on androgens:

It blocks androgen receptors on sebocytes, the oil-producing cells, so DHT can't dock and trigger oil production.
It interferes with 5-alpha-reductase, the enzyme that converts testosterone into the more potent DHT inside the skin.
It nudges down the body's own testosterone production and helps clear it faster.

The net result is less sebum. In one early dosing study, sebum production dropped in a dose-dependent way, meaning higher doses cut oil more than lower ones. Less oil means fewer clogged pores, fewer inflamed bumps, and less of the greasy shine many patients hate. You can read more about how oil and pore biology drive breakouts in our dermatologist night routine for acne.

One detail worth understanding: spironolactone does not "balance your hormones" in any global sense, despite how it's often described online. It doesn't fix a hormone imbalance the way you'd treat a thyroid problem. Most women with hormonal acne actually have normal blood levels of testosterone. The issue is usually how sensitive their oil glands are to normal androgen levels, not the amount of androgen floating in the bloodstream. Spironolactone works at the receptor in the skin, blocking the signal locally. That's a meaningful distinction, because it explains why the drug can help women whose lab work looks completely normal, and why "getting your hormones tested" before starting often isn't necessary unless there are other signs of a hormonal disorder like polycystic ovary syndrome (PCOS).

Why oral and not topical

You might wonder why this is a pill and not a cream, since acne is a skin condition. Researchers have tried topical spironolactone, and some small studies exist, but the topical form has never gained real traction or strong evidence in the United States. The oral route is what every major trial has tested, and it's what the FDA-approved drug delivers. The trade-off is that taking it by mouth affects the whole body, which is the source of both its broader benefits (it can also help conditions like female pattern hair loss and excess facial hair) and its whole-body side effects.

The evidence: what the trials actually show

For most of its history, spironolactone for acne rested on small studies, case series, and clinical habit. A widely cited 2017 systematic review found the data thin and called for better trials. That gap has finally started to close.

The SAFA trial: the strongest single study

The most important piece of evidence is the SAFA trial (Spironolactone for Adult Female Acne), a phase 3, double-blind, placebo-controlled randomized trial run across England and Wales and published in 2023. It enrolled 410 women with persistent facial acne. Half got spironolactone, half got placebo. Patients started at 50 mg a day, then moved up to 100 mg a day after six weeks, and continued to week 24. This is the largest, most rigorous trial of its kind, which is why it carries so much weight.

The results were positive but worth reading carefully:

The main outcome was an acne quality-of-life score at week 12. Spironolactone beat placebo, but the gap was small (a difference of 1.27 points on the symptom subscale, just clearing statistical significance).
By week 24, the gap widened a lot. The quality-of-life difference grew to 3.45 points, and far more women rated their acne as improved (about 82% on the drug versus 63% on placebo).
Investigator-rated treatment success at week 12 was much higher on spironolactone: 31 of 201 women succeeded versus 9 of 209 on placebo, an odds ratio of about 5.2.

The honest read: spironolactone works, but slowly. The week-12 benefit was modest and the patient-reported improvement at that point wasn't even statistically significant. The drug needed about six months to show its full effect. Anyone expecting fast results will be disappointed.

What the meta-analyses found

Pooling trials together strengthens the picture. Two 2025 meta-analyses are worth knowing.

A meta-analysis in the Australasian Journal of Dermatology pooled randomized trials in adult women with moderate-to-severe acne. Spironolactone roughly doubled the odds of treatment success versus placebo or the antibiotic doxycycline, with a pooled odds ratio of about 2.5.

A second meta-analysis in the Journal of Cosmetic Dermatology pooled five placebo-controlled trials covering 563 patients, 251 of whom took spironolactone. Objective acne improvement was about six times more likely on the drug than on placebo (odds ratio 6.59). The authors went so far as to argue spironolactone should move from off-label status to a recommended standard of care for women.

Evidence summary table

Source (year)	Design	Patients	Key finding	Honest grade
SAFA trial (2023)	Phase 3 RCT, placebo-controlled	410 women	Modest benefit at week 12; clear benefit by week 24 (82% vs 63% improved)	Strongest single trial; benefit real but slow
Aust J Dermatol meta-analysis (2025)	Pooled RCTs	Multiple trials	~2.5x odds of treatment success vs placebo/doxycycline	Moderate; few large trials to pool
J Cosmet Dermatol meta-analysis (2025)	Pooled placebo RCTs	563	~6.6x odds of objective improvement vs placebo	Moderate; consistent direction, small total N
2017 systematic review	Hybrid review	Mixed	Limited high-quality data; called for trials	Historically weak, now improving

Where the evidence is still weak

It's worth being blunt about the limits, because the marketing around spironolactone often isn't.

The total number of patients in good randomized trials is still small. A few hundred is modest for a drug used by huge numbers of women.
SAFA's week-12 result barely cleared significance, and the benefit took six months to mature. The headline odds ratios sound dramatic but sit on small trials.
Almost all evidence is in women. There's very little data on men, and the side-effect profile (breast tissue growth, feminization) makes it a poor fit for most men anyway.
Few head-to-head trials pit spironolactone against the real-world alternatives like oral contraceptives or isotretinoin. We know it beats placebo. We know much less about how it ranks against its competitors.
Older dosing studies and the strongest meta-analysis push toward doses above 100 mg, yet much real-world prescribing stays at 50 to 100 mg. The dose-response question isn't fully settled.

That said, the trend is encouraging. The evidence in 2026 is far better than it was a decade ago, and it points consistently in one direction: spironolactone helps women with hormonal acne.

A note on study funding and bias

It's fair to ask who paid for the research, because that shapes how much to trust it. Here the news is reassuring. The SAFA trial was funded by the United Kingdom's National Institute for Health and Care Research, a public body with no product to sell. Spironolactone is a cheap, generic, off-patent drug, so no pharmaceutical company has a strong financial reason to push it. That's the opposite of the usual situation with branded skincare ingredients, where the company selling the product also funds the studies. So while the trials are small, they're largely free of the industry-funding bias that taints a lot of cosmetic and supplement research. When you read a claim that spironolactone "doubles" or "sextuples" the odds of clear skin, the bias risk isn't a sponsor cooking the books. It's the simpler problem of small sample sizes producing wide, sometimes shaky confidence intervals.

Dosing and what to expect

There's no FDA-approved acne dose, so prescribing comes from trials and clinical experience. Most dermatologists start low and work up.

Stage	Typical dose	Notes
Starting dose	25-50 mg/day	Low start limits side effects; some clinicians begin at 50 mg
Common maintenance	50-100 mg/day	The range used in the SAFA trial
Higher dosing	100-200 mg/day	Older studies suggest more benefit above 100 mg; more side effects
Time to judge	3-6 months	Benefit builds slowly; six months is a fair trial before giving up

A few practical points. Spironolactone is often combined with a topical retinoid or with an oral contraceptive, which can boost results and (with the pill) add birth control that matters for this drug. Taking it with food can ease stomach upset. And patience is the rule. If you quit at week 8 because nothing changed, you may have stopped right before it started working. For how oral treatments fit alongside topicals, see our retinoids and actives complete research-based guide.

How to combine it for better results

Spironolactone rarely works best alone. Most dermatologists treat it as one layer in a routine rather than a standalone fix. Here's how the common pairings work and why.

With a topical retinoid (adapalene, tretinoin). Retinoids unclog pores and speed up cell turnover, which tackles a different part of acne than spironolactone's oil control. The two attack the problem from separate angles, so they stack well. Many regimens pair nightly retinoid use with daily spironolactone. If you're choosing between the two most common options, our adapalene vs tretinoin comparison breaks down the differences.
With a combined oral contraceptive. This is a popular combo for women, and not just for acne. The pill adds reliable pregnancy prevention (which matters because spironolactone is risky in pregnancy), helps regulate the menstrual irregularities spironolactone can cause, and brings its own modest anti-acne effect by lowering free androgens. The downside is the pill's own risks, including a small increase in blood clot risk.
With benzoyl peroxide or topical antibiotics. These target acne-causing bacteria and inflammation. They're often kept in the routine to handle the inflammatory side of breakouts while spironolactone handles oil.
As an antibiotic-sparing option. One of spironolactone's biggest practical advantages is that it lets women come off long-term oral antibiotics. Long courses of antibiotics drive bacterial resistance and disrupt the gut, so swapping in a non-antibiotic maintenance drug is a genuine win. This antibiotic-sparing role is a big reason it's gained favor in recent guidelines.

What spironolactone is usually not paired with is isotretinoin, since that drug is typically reserved for the most severe, scarring cases and follows its own strict protocol. If your acne is at that level, the conversation shifts. Our guide to the best in-office treatments for acne scars covers what happens after acne leaves marks behind.

Safety: the real risks, in plain terms

Spironolactone is generally well tolerated in healthy young women, but it's not free of risk. Here's an honest rundown.

Hyperkalemia (high potassium). This is the scary-sounding one, because severe high potassium can affect the heart. The good news: it's rare in healthy young women. A large study in JAMA Dermatology found that healthy young women (aged 18 to 45) taking spironolactone for acne had a hyperkalemia rate of about 0.72%, basically the same as the baseline rate in women not on the drug (0.76%). Because of this, the 2024 American Academy of Dermatology acne guidelines no longer recommend routine potassium monitoring for healthy young patients without risk factors. Older women are a different story. A 2019 study found a meaningfully higher rate of high potassium in women over 45, so monitoring still makes sense there, and for anyone with kidney problems or on interacting drugs.

Menstrual changes and breast tenderness. Irregular periods and breast tenderness or enlargement are the most common reasons women stop. Reassuringly, the 2025 meta-analysis found no statistically significant increase in menstrual irregularities or breast enlargement versus placebo, though individual experiences vary. Combining spironolactone with an oral contraceptive often smooths out cycle issues.

Pregnancy risk. This matters. Spironolactone can interfere with the normal development of a male fetus's genitals because of its anti-androgen action. It should not be used in pregnancy, and most clinicians want women on reliable birth control while taking it. If you could become pregnant, this is a non-negotiable conversation to have with your prescriber.

Other effects. Dizziness, fatigue, headache, and increased urination (it's a diuretic) can happen, especially early on. They often fade.

The rat tumor question. You may run across alarming claims online about cancer. Here's the accurate version. The FDA label notes that spironolactone "has been shown to be a tumorigen in dietary administration studies performed in rats" at high doses. That finding is in rats, not humans. Large human studies have not shown a convincing increase in cancer risk in women using it, but this is an area where long-term human data is still imperfect, and it's why the drug shouldn't be used without a real reason.

Who should not take it

Group	Why
People who are or may become pregnant	Risk to male fetal development
People with significant kidney disease	Higher hyperkalemia risk; reduced clearance
People with already-high potassium	Drug raises potassium further
People on certain heart/BP drugs (ACE inhibitors, ARBs, potassium supplements)	Combined hyperkalemia risk
Most men with acne	Feminizing side effects usually outweigh benefit

How it compares to the alternatives

Spironolactone is one tool among several for hormonal acne. None is clearly "best" for everyone.

Option	Best for	Speed	Main downsides
Spironolactone	Adult women, jawline/hormonal acne, oily skin	Slow (3-6 months)	Pregnancy risk, period changes, off-label
Combined oral contraceptives	Women wanting acne control plus birth control	Slow (3-6 months)	Blood clot risk, not for everyone
Oral antibiotics (doxycycline)	Inflammatory acne, short-term	Faster	Resistance, gut effects, not for long-term use
Topical retinoids	Mild-to-moderate, maintenance	Slow	Irritation, dryness
Isotretinoin	Severe, scarring, treatment-resistant acne	Months, often curative	Strict monitoring, pregnancy program, dryness

A reasonable way to think about it: spironolactone and the pill are the two hormone-targeting oral options, and they pair well together. Antibiotics work faster but aren't meant for the long haul, which is part of spironolactone's appeal as a non-antibiotic maintenance option. Isotretinoin is the heavy artillery for the worst, scarring cases. For a fuller comparison of in-office and prescription routes, see our best in-office treatments for acne scars and the broader retinoids and actives guide.

Who is a good candidate

The evidence points to a fairly specific person. Spironolactone is most likely to help if you are:

An adult woman, not pregnant and using reliable birth control.
Dealing with hormonal-pattern acne (lower face, jawline, neck), oily skin, or premenstrual flares.
Frustrated by acne that resists topicals or keeps coming back after antibiotics.
Willing to give it three to six months before judging results.
Free of significant kidney disease or high potassium.

It's a weaker fit if you have inflammatory acne all over the face without a hormonal pattern, if you're a man, if you could become pregnant and won't use contraception, or if you need fast results for an event next month. And if your acne is severe and scarring, the conversation may shift toward isotretinoin instead.

The bottom line

Spironolactone has gone from a habit-based, thinly studied off-label drug to one with genuine randomized-trial support for adult women with hormonal acne. The SAFA trial and two 2025 meta-analyses agree it beats placebo. But read the fine print: the benefit is real yet modest at first, builds over months, rests on a still-small body of trials, and almost entirely applies to women. It's safe enough that healthy young women usually don't need blood tests, but it carries a firm pregnancy warning. For the right person, it's one of the better-evidenced options in the hormonal-acne toolkit. For the wrong person, it's the wrong drug. That's a call to make with a clinician, not a search bar.

Frequently Asked Questions

How long does spironolactone take to work for acne?

Slower than most people expect. In the SAFA trial, the benefit at week 12 was modest, and the clear improvement showed up by week 24. Most clinicians say give it a full three to six months before deciding it isn't working.

Do I need blood tests to monitor potassium on spironolactone?

For healthy young women without kidney disease or interacting medications, usually no. Studies and the 2024 American Academy of Dermatology guidelines found routine potassium monitoring isn't high value in this group, because hyperkalemia is rare. Monitoring still makes sense for women over 45, people with kidney problems, or those on certain heart and blood pressure drugs.

Can men take spironolactone for acne?

It's rarely used in men. Because the drug blocks androgens, men can develop breast tissue growth and other feminizing effects, which usually outweighs the acne benefit. Almost all the good evidence is in women.

Is spironolactone safe during pregnancy?

No. Its anti-androgen action can interfere with normal development of a male fetus, so it shouldn't be used in pregnancy. Most prescribers want women on reliable birth control while taking it.

Does spironolactone cause cancer?

Animal studies showed it can be a tumor-causing agent in rats given high doses, and that note appears on the FDA label. That finding is in rats, not humans, and large human studies have not shown a convincing cancer increase in women using it for acne. Long-term human data isn't perfect, which is why it shouldn't be taken without a clear reason.

This article is for general information only and is not medical advice. Spironolactone is a prescription medication with real risks. Talk to a qualified healthcare provider before starting, stopping, or changing any treatment.